{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:10:27Z","timestamp":1792282227020,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clgc.2014.03.009","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T14:18:19Z","timestamp":1395929899000},"page":"440-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"Gregory R.","family":"Pond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Kolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.03.009_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2014.03.009_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/annonc\/mds635","article-title":"Penile cancer: current therapy and future directions","volume":"24","author":"Sonpavde","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib3","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1111\/j.1464-410X.2012.11453.x","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2014.03.009_bib4","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/02841868809094366","article-title":"Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis","volume":"27","author":"Pizzocaro","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2007.02.006","article-title":"Neoadjuvant chemotherapy in advanced penile carcinoma","volume":"52","author":"Leijte","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1464-410X.2006.06496.x","article-title":"Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma","volume":"98","author":"Hakenberg","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2014.03.009_bib8","first-page":"1335","article-title":"Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma","volume":"177","author":"Bermejo","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib9","first-page":"1284","article-title":"Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract","volume":"146","author":"Dexeus","year":"1991","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2008.07.014","article-title":"Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results","volume":"55","author":"Pizzocaro","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ucl.2010.04.010","article-title":"Chemotherapy for penile and urethral carcinoma","volume":"37","author":"Trabulsi","year":"2010","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2014.03.009_bib12","first-page":"630","article-title":"Cisplatin and 5-fluorouracil in advanced cancer of the penis","volume":"147","author":"Shammas","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.urolonc.2007.10.015","article-title":"Cisplatin and gemcitabine in the management of metastatic penile cancer","volume":"27","author":"Power","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib14","first-page":"66","article-title":"cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study","volume":"141","author":"Gagliano","year":"1989","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib15","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"issue":"suppl","key":"10.1016\/j.clgc.2014.03.009_bib16","article-title":"Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis","volume":"29","author":"Salvioni","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdn149","article-title":"A\u00a0phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC protocol 30992)","volume":"19","author":"Theodore","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archdermatol.2009.160","article-title":"Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy","volume":"145","author":"Eliason","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clgc.2014.03.009_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00000421-199312000-00009","article-title":"Combined modality therapy for\u00a0locally advanced penile squamous cell carcinoma","volume":"16","author":"Pedrick","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2013.0076","article-title":"Current concepts in penile cancer","volume":"11","author":"Spiess","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2014.03.009_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-008-0310-z","article-title":"Multimodality therapy in penile cancer: when and which treatments?","volume":"27","author":"Pagliaro","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2013.0075","article-title":"Penile cancer: clinical practice guidelines in oncology","volume":"11","author":"Clark","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2014.03.009_bib23","doi-asserted-by":"crossref","unstructured":"Pond GR, Di Lorenzo G, Necchi A, et\u00a0al. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy [published online December 12, 2013]. Urol Oncol. http:\/\/dx.doi.org\/10.1016\/j.urolonc.2013.10.007.","DOI":"10.1016\/j.urolonc.2013.10.007"},{"key":"10.1016\/j.clgc.2014.03.009_bib24","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2014.03.009_bib25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.urology.2011.11.070","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy","volume":"79","author":"Gondo","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2014.03.009_bib26","first-page":"411","article-title":"Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma","volume":"187","author":"Ohno","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.009_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/1354750X.2012.656705","article-title":"Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer","volume":"17","author":"Kwon","year":"2012","journal-title":"Biomarkers"},{"key":"10.1016\/j.clgc.2014.03.009_bib28","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.urolonc.2011.09.008","article-title":"The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma","volume":"31","author":"Sejima","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2014.03.009_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jso.21986","article-title":"Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer","volume":"104","author":"Jung","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clgc.2014.03.009_bib31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2014.03.009_bib32","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2012-0125","article-title":"Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram","volume":"17","author":"Keizman","year":"2012","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:52Z","timestamp":1761564232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1558767314000585"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.009","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}